Search IPOs
HNIL · BSE · Food Products
Himalaya Nutravedics India IPO listed on 29 Sep 2026 on BSE at ₹118.00, a gain of 11.32% over the issue price of ₹106.00. The IPO was subscribed 2.31x overall.
Himalaya Nutravedics India IPO tentative timeline covering IPO opening, closing, basis of allotment, refunds, demat credit, and listing dates.
| Event | Date |
|---|---|
| IPO Open Date | 22 Sep 2026 |
| IPO Close Date | 24 Sep 2026 |
| Basis of Allotment | 25 Sep 2026 |
| Initiation of Refunds | 28 Sep 2026 |
| Credit of Shares to Demat | 28 Sep 2026 |
| Listing Date | 29 Sep 2026 |
Listing day gain
+11.32%
Listed at ₹118 (issue ₹106)
Issue
₹106
Listing
₹118
Current
₹120
+13.21% vs issue
Day range
₹118 – ₹123.9
Issue Size
2,499,600 shares
(aggregating up to ₹26.00 Cr)
Issue Price
₹100 – ₹106
Face Value
₹10/share
Market Lot
1,200 shares
Retail Min Investment
₹254,400
Listing At
BSE
Sale Type
fresh issue
Fresh Issue
2,373,600 shares
(aggregating up to ₹25 Cr)
Offer for Sale
[.]
Reserved for Market Maker
126,000 shares
(aggregating up to ₹1.00 Cr)
Issue Type
book building
Open Date
22 Sep
Close Date
24 Sep
Allotment
25 Sep
Listing
29 Sep
Last updated: 1 week ago
| Date | IPO Issue Price (₹) | GMP (₹) | Est. Listing Price (₹) | Est. Profit Amount (₹) | Est. Profit % | Last Updated |
|---|---|---|---|---|---|---|
| 28 Sep 2026 Latest | ₹106 | ₹0 | ₹106 | ₹0 |
0%
|
9:30 PM |
| 28 Sep 2026 | ₹106 | ₹0 | ₹106 | ₹0 |
0%
|
9:00 PM |
Showing the 2 most recent GMP entries.
View full GMP historyLatest snapshot: 24 Sep 2026
| Category | Subscribed (x) | No. of Applications |
|---|---|---|
| QIB | 1x | - |
| NII | 3.48x | - |
| bNII (bids above ₹10L) | 3.84x | - |
| sNII (bids below ₹10L) | 2.77x | - |
| Individual Investors | 2.55x | - |
| Total | 2.31x | - |
Showing the latest subscription snapshot.
View full subscription historyRohit Asawa, Divya Asawa, Chanda Asawa, and Rama Raju Penmatsas are the promoters of the company.
New to lot sizes and investment limits? Read our guide on IPO lot size and minimum investment.
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,400 | ₹254,400 |
| Retail (Max) | 2 | 2,400 | ₹254,400 |
| S-HNI (Min) | 3 | 3,600 | ₹381,600 |
| S-HNI (Max) | 7 | 8,400 | ₹890,400 |
| B-HNI (Min) | 8 | 9,600 | ₹1,017,600 |
Want to understand how IPO shares are divided between investor categories? Read our guide on IPO reservation structure.
| Category | Shares Offered |
|---|---|
| QIB Shares Offered | 1,184,400 (47.38%) |
|
•
Anchor Investor Shares Offered
|
710,400 (28.42%) |
|
•
QIB (Ex. Anchor) Shares Offered
|
474,000 (18.96%) |
| NII (HNI) Shares Offered | 356,400 (14.26%) |
|
•
bNII > ₹10L
|
237,600 (9.51%) |
|
•
sNII < ₹10L
|
118,800 (4.75%) |
| Individual Investors Shares Offered | 832,800 (33.32%) |
| Market Maker Shares Offered | 126,000 (5.04%) |
| Total Shares Offered | 2,499,600 (100.00%) |
Ancient wisdom doesn't have to stay ancient. Himalaya Nutravedics India Limited was built on exactly that idea taking the depth of Ayurvedic tradition and translating it into products that meet the standards of modern science.
Incorporated in 2022 and headquartered in Hyderabad, Telangana, the company operates from a GMP-certified manufacturing facility in Cherlapally Industrial Development Park. In a relatively short span, it has carved out a credible space in India's fast-growing Ayurvedic and nutraceutical sector manufacturing, marketing, and distributing a wide range of wellness formulations across multiple dosage forms including soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils.
What makes Himalaya Nutravedics stand apart is the dual nature of its business. Alongside its own branded formulations both classical Shastric Ayurvedic products and proprietary blends the company also offers full-spectrum contract manufacturing and private labelling services for other wellness brands. This B2B angle gives it a steady, scalable revenue stream beyond just retail.
In FY25, the company posted revenues of ₹21.5 crore, clocking a remarkable 49% revenue CAGR a strong signal for a young company in a high-demand sector.
Standalone · ₹ in Crores
| Particulars | FY Mar 2024 | FY Mar 2025 | FY Mar 2026 |
|---|---|---|---|
| Total Revenue | 14.43 | 21 | 43.12 |
| Profit After Tax (PAT) | 0.43 | 2.23 | 7.39 |
| EBITDA | 0.94 | 2.99 | 8.1 |
| Total Assets | 6.09 | 10.82 | 24.42 |
| Net Worth | 1.34 | 6.75 | 16.38 |
| Reserves & Surplus | 0.53 | 2.76 | 10.07 |
| Total Borrowing | 3.24 | 1.76 | 5.13 |
Revenue & Profit Trend
Key ratios per fiscal period
| Particulars | Mar 2026 |
|---|---|
| RoE Return on Equity Shows how much profit the company makes on the money shareholders have put in. 15% to 20% is healthy in most industries. | 63.87% |
| RoCE Return on Capital Employed Shows the profit earned on all the money used, shareholder funds plus loans. Matters most for factory and infrastructure heavy companies. | 36.41% |
| RoNW Return on Net Worth Shows the profit earned on the company's own net worth. Steady or rising over 3 years is a good sign. | 45.12% |
| PAT Margin Profit After Tax Margin Out of every ₹100 of sales, how much the company keeps after paying all costs, loan interest and tax. | 17.16% |
| EBITDA Margin Earnings Before Interest, Tax, Depreciation and Amortisation Margin Profit from the main business as a share of sales, before loan interest and tax. Compare it with other companies in the same industry. | 18.52% |
| Debt / Equity Debt to Equity How much the company has borrowed against what shareholders own. Above 1x means the loans are bigger than shareholder funds. | 0.31x |
| P/BV Price to Book Value Tells you if the IPO price is above what the company actually owns. 1x to 3x is usually seen as reasonable. | 3.97x |
Issue-level · at the upper price band
| Particulars | Pre-IPO | Post-IPO |
|---|---|---|
| EPS Earnings Per Share Profit the company earns on each share. Post-IPO EPS is usually lower because the issue adds new shares. | ₹11.72 | ₹8.39 |
| P/E Price to Earnings Tells you if the IPO price is fair for what the company earns. Compare it with listed companies in the same sector. | 9.04x | 12.63x |
| Market Cap Market Capitalisation What the whole company is valued at, at the upper price band. Post-IPO counts the new shares the issue creates. | ₹67 Cr | ₹94 Cr |
The basis of allotment for Himalaya Nutravedics India IPO was finalised on 25 Sep 2026. You can check your allotment status using your PAN number or application number on the KFin Technologies Limited portal or BSE.
The Himalaya Nutravedics India IPO is expected to open in Sep 2026, subject to SEBI approval. Final dates will be updated once announced officially.
The price band for Himalaya Nutravedics India IPO is ₹100.00 - ₹106.00 per share.
As per market sources, Himalaya Nutravedics India IPO GMP is currently ₹0.00. GMP is tracked daily in the grey market. GMP indicates unofficial demand but does not guarantee listing gains.
The subscription status for Himalaya Nutravedics India IPO stands at 2.31x overall.
The listing date for Himalaya Nutravedics India IPO is 29 Sep 2026.
No comments yet. Be the first to comment!
